Q2 Earnings Forecast for Verastem Issued By HC Wainwright

Verastem, Inc. (NASDAQ:VSTM) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings estimates for shares of Verastem in a note issued to investors on Wednesday, June 24th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings per share of ($0.47) for the quarter, down from their previous estimate of ($0.45). HC Wainwright has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Verastem’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Verastem’s Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.70) EPS, FY2028 earnings at ($0.82) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.58 EPS.

A number of other research firms have also issued reports on VSTM. Alliance Global Partners reissued a “buy” rating on shares of Verastem in a report on Friday, May 8th. Mizuho decreased their price objective on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Thursday, May 14th. Jefferies Financial Group lowered their target price on Verastem from $15.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. BTIG Research reissued a “buy” rating and issued a $18.00 price objective on shares of Verastem in a research note on Wednesday. Finally, Wall Street Zen downgraded Verastem from a “hold” rating to a “sell” rating in a research note on Saturday, June 20th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $14.60.

Verastem Price Performance

Shares of NASDAQ:VSTM opened at $3.45 on Friday. Verastem has a one year low of $3.43 and a one year high of $11.24. The stock has a market capitalization of $303.15 million, a price-to-earnings ratio of -1.28 and a beta of 0.27. The company has a 50-day simple moving average of $4.70 and a 200-day simple moving average of $5.92. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.00 and a current ratio of 3.04.

Institutional Investors Weigh In On Verastem

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its position in Verastem by 182.9% during the third quarter. Russell Investments Group Ltd. now owns 4,578 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 2,960 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Verastem by 110.9% in the third quarter. BNP Paribas Financial Markets now owns 8,550 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 4,496 shares during the last quarter. E Fund Management Co. Ltd. purchased a new position in Verastem during the second quarter worth about $49,000. DRW Securities LLC purchased a new position in Verastem during the fourth quarter worth about $93,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Verastem during the 2nd quarter worth about $53,000. Hedge funds and other institutional investors own 88.37% of the company’s stock.

Insiders Place Their Bets

In other Verastem news, CEO Dan Paterson sold 20,871 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $4.18, for a total transaction of $87,240.78. Following the completion of the transaction, the chief executive officer directly owned 591,242 shares in the company, valued at approximately $2,471,391.56. This trade represents a 3.41% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.94% of the company’s stock.

More Verastem News

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Verastem and maintained an $18 price target, signaling continued upside potential despite trimming near- and long-term earnings forecasts.
• Positive Sentiment: BTIG Research also reiterated a Buy rating with an $18 price objective, and the broader analyst consensus remains a Moderate Buy.
• Neutral Sentiment: Verastem continues to draw attention from investors after recent commentary around its KRAS-targeted combination therapy and updated safety/efficacy findings from the RAMP 205 study, which could remain an important long-term driver if clinical data improves.
• Neutral Sentiment: Short interest was reported at 0 shares, so there is no clear short-interest pressure or squeeze setup indicated in the latest data.
• Negative Sentiment: HC Wainwright reduced earnings estimates across multiple periods, including Q2 2026 EPS to -$0.47, Q3 2026 to -$0.46, Q4 2026 to -$0.40, and FY2026 to -$1.70, suggesting a slower path to profitability than previously expected.
• Negative Sentiment: The firm also cut longer-term forecasts, including FY2028 EPS to -$0.82, FY2029 EPS to -$0.34, and FY2030 EPS to $0.58, which may reinforce concerns about delayed earnings improvement.
• Negative Sentiment: Recent insider selling by CEO Dan Paterson and CFO Daniel Calkins may add some near-term caution, even though both trades were made under pre-arranged trading plans.

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.